Quarterly ResultMay 18, 2026, 07:27 AM
ABVC BioPharma Reports Q1 Net Loss $1.69M; Going Concern Doubt
AI Summary
ABVC BioPharma reported a net loss of $1,689,937 for the three months ended March 31, 2026, an increase from the $944,190 net loss in the prior year period. The company also disclosed a working capital deficit of $4,744,280 and net cash outflows of $894,243 from operating activities, raising substantial doubt about its ability to continue as a going concern. Management plans to improve operations and seek additional capital through offerings or related party support.
Key Highlights
- Net loss for Q1 2026 was $(1,689,937), compared to $(944,190) in Q1 2025.
- Working capital deficit as of March 31, 2026, was $(4,744,280).
- Net cash used in operating activities for Q1 2026 was $(894,243).
- Total operating expenses for Q1 2026 increased to $1,572,472 from $693,005.
- Cash and cash equivalents decreased to $140,324 from $681,480 at Dec 31, 2025.
- Stock-based compensation rose to $787,374 from $48,773 in Q1 2025.
- Total Assets decreased to $19,732,528 from $21,062,203 at Dec 31, 2025.
Price Impact
More from ABVC